Veraxa Biotech AG - Post de-SPAC VRXA
Veraxa Biotech AG - Post de-SPAC (Nasdaq: VRXA) is an oncology drug developer. Its lead program, VX-A901 (FLYSIN), is in Phase 1 for acute myeloid leukemia (AML).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VX-A901 (FLYSIN, anti-FLT3 antibody with modified Fc) | acute myeloid leukemia | antibody | Phase 1 |
| EpCAMxCDH3 BiTAC-TCE T cell engager | solid tumors | antibody | Pre-clinical |
| HER3xNEC4 BiTAC (bispecific ADC) | solid tumors | antibody | Pre-clinical |
| OmniAb joint-venture bispecific ADC | solid tumors | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.